Table 3 Demographic data of the internal controls in the present study
Number | Age | Sex | BMI | ASA score | Preoperative ENBD | Diagnosis |
|---|---|---|---|---|---|---|
1 | Male | 63 | 23.3 | II | No | Pancreatic head cancer |
2 | Male | 52 | 18.8 | II | No | CBD cancer |
3 | Female | 59 | 32.4 | II | Yes | Pancreatic head cancer |
4 | Female | 57 | 24.1 | II | No | CBD cancer |
5 | Male | 51 | 21.0 | II | No | Pancreatic head cancer |
6 | Male | 52 | 24.0 | II | Yes | Pancreatic head cancer |
7 | Male | 45 | 23.6 | I | No | Duodenal cancer |
8 | Male | 50 | 18.8 | II | Yes | Duodenal cancer |
9 | Male | 76 | 24.1 | II | No | CBD cancer |
10 | Male | 69 | 21.9 | II | No | CBD cancer |
11 | Female | 76 | 18.1 | II | No | CBD cancer |
12 | Female | 73 | 22.9 | III | Yes | Pancreatic head cancer |
13 | Female | 57 | 23.4 | I | No | Pancreatic head cancer |
14 | Male | 75 | 21.3 | II | Yes | AOV cancer |
15 | Female | 73 | 29.1 | II | Yes | CBD cancer |
16 | Male | 53 | 26.6 | II | No | Pancreatic head IPMN |
17 | Female | 30 | 17.2 | I | No | Pancreatic head cancer |
18 | Male | 74 | 25.7 | II | No | Pancreatic head cancer |
19 | Male | 62 | 24.1 | III | Yes | Pancreatic head IPMN |
20 | Female | 72 | 23.1 | III | No | Pancreatic head cancer |
21 | Female | 58 | 23.8 | II | No | CBD cancer |
22 | Male | 77 | 23.1 | II | No | CBD cancer |
23 | Male | 71 | 18.5 | II | Yes | Pancreatic head cancer |
24 | Male | 58 | 24.8 | II | No | Pancreatic head cancer |
25 | Male | 66 | 18.7 | II | Yes | Pancreatic head cancer |
26 | Male | 50 | 18.2 | II | No | AGC |
27 | Female | 60 | 20.0 | II | No | Duodenal GIST |
28 | Male | 59 | 18.8 | II | No | Pancreatic head cancer |
29 | Male | 65 | 25.3 | III | No | AOV cancer |
30 | Male | 72 | 27.4 | II | Yes | CBD cancer |
31 | Female | 78 | 19.8 | II | Yes | CBD cancer |